OVID Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Ovid Therapeutics Inc is not a strong buy at this moment for a beginner investor with a long-term strategy. The stock lacks significant positive catalysts, and its financial performance is weak. While the technical indicators show some bullish trends, the lack of strong proprietary trading signals, poor financials, and hedge fund selling suggest holding off on investment for now.
The MACD is positive and expanding, indicating bullish momentum. RSI is neutral at 69.621. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key resistance levels are at 1.629 and 1.703, while support levels are at 1.393 and 1.319.
Analyst ratings are positive with Outperform and Buy ratings, and price targets of $3 and $4, suggesting potential upside.
Hedge funds are selling heavily, with a 668.25% increase in selling activity. Financial performance is weak, with declining revenue, net income, and EPS in the latest quarter. No recent news or congress trading data to support positive sentiment.
In Q3 2025, revenue dropped by -23.70% YoY to $132,000. Net income declined by -13.19% YoY to -$12.16 million. EPS fell by -15.00% YoY to -0.17. Gross margin remained flat at 100%.
LifeSci Capital initiated coverage with an Outperform rating and $4 price target. Roth Capital rated it a Buy with a $3 price target, citing the potential of OV329 in the epilepsy therapy market.
